Lacosamide Hikma (Lacosamide)

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

• Partial‑onset seizures: reduces the frequency and severity of focal seizures when used as adjunct therapy.
• Epilepsy (focal epilepsy): contributes to overall seizure control as part of a multi‑drug regimen.
• Adjunctive therapy for refractory seizures: provides additional seizure reduction when first‑line agents are insufficient.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes and decreasing repetitive neuronal firing. This selective modulation reduces neuronal excitability without affecting the fast inactivation phase, thereby limiting the propagation of epileptic discharges.

Lacosamide may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects

• Dizziness: sensation of light‑headedness or imbalance.
• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or throbbing pain.
• Fatigue: increased tiredness or lack of energy.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, including atrioventricular block.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Respiratory depression: slowed breathing, especially with CNS depressants.
• Hepatic failure: signs of liver dysfunction.
• Anaphylaxis: rare severe allergic response.

Before initiating lacosamide therapy, consider the following safety measures.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution and observe liver enzymes.
• Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes.
• Pregnancy: risk category unknown; discuss potential benefits and risks with a healthcare professional.
• Concomitant CNS depressants: may increase sedation; observe patient closely.
• Store at room temperature: keep in the original container, protect from moisture and light.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Class I antiarrhythmics: may exacerbate cardiac conduction effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise lacosamide plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampicin): may lower lacosamide levels, reducing effectiveness.

Moderate Interactions (Monitor Closely)

• Carbamazepine: additive CNS depression and possible pharmacokinetic changes.
• Phenobarbital: may decrease lacosamide efficacy.
• Alcohol: can enhance dizziness and sedation.